Researchers at National Jewish Health have discovered a trigger that induces B cells to produce effective and long-lived antibodies early in the immune response. They found that a molecule that binds toll-like receptors (TLR) doubles the early antibody response to an antigen, and shifts it to a more effective, IgG form.
The findings, published online and in the July 5, 2010, issue of the Journal of Experimental Medicine, support the emerging concept of ‘bridge immunity,’ which links the innate and adaptive arms of the immune response. They may also lead to the development of better vaccines.
“In our experiments, a molecule that interacts with the innate immune system stimulates follicular B cells, which are recognized as part of the adaptive immune system,” said senior author Raul Torres, PhD, Associate Professor of Immunology at National Jewish Health. “Our data provide evidence of a continuous immune response, rather than two distinct and separate arms.”
A gap in the immune response?
The innate immune response begins within minutes to hours after an infection begins by recognizing general molecular patterns associated with infectious organisms, such as components of bacterial cell walls. It is rapid but not particularly focused. The adaptive immune response detects proteins associated with specific invaders, and ultimately produces highly targeted antibodies that help neutralize foreign organisms. That process begins several days after the infection has begun, and does not reach full strength for 10 days to two weeks on average.
For many years, scientists thought the two arms of the immune response acted separately and independently. If that were true, however, there would be a gap in protection after the innate response fades and before the adaptive response kicks in. In recent years, scientists have begun realizing that the two arms of the immune system communicate with each other to fill that gap.
Dr. Torres and Cristina L. Swanson PhD, a postdoctoral fellow in his lab, studied a process that contains elements of both innate and adaptive immunity, known as the T-cell independent antibody response. While B cells are most widely recognized for their contributions to the adaptive immune response, some begin producing antibodies soon after an infection begins. Instead of detecting a single specific protein associated with the invader, they detect repetitive molecules linked together, such as those found in a bacterial cell wall or viral capsid.
This process has been studied for many years using synthetic molecules as model antigens. Drs. Torres Swanson thought that experiments using just the synthetic antigens did not accurately reflect what occurs in the real world. They reasoned that B cells would almost never encounter a bacterial cell wall or viral capsid alone; an intact cell wall would almost always also contain other molecules that activate the innate immune response as well. So the researchers decided to inject mice with the synthetic antigen plus a molecule that binds an innate receptor, known as TLR ligand. Dr. Swanson performed the majority of the experiments as part of her doctoral thesis work.
Striking results
The results were striking. Early antibody levels doubled when the TLR ligand was added. The mix of antibodies shifted as well, from 61 percent IgM to 82 percent IgG, which is a highly effective weapon against disease-causing organisms. The IgG levels remained elevated in mice for 182 days, as long as the researchers measured them. The long-lived persistence of this effective antibody suggests that the observations could be adapted to make more effective vaccines.
The researchers found that the TLR ligand spurred other cells to release type I interferon. That, in turn, activated follicular B cells to release the IgG antibodies. Prior to that, scientists had believed that follicular B cells participated in the adaptive immune response later during the infection.
“Our experiments not only provide further evidence for bridge immunity, but also demonstrate a precise mechanism by which it occurs,” said Dr. Swanson, first author on the paper.
National Jewish Health is known worldwide for treatment of patients with respiratory, cardiac, immune and related disorders, and for groundbreaking medical research. Founded in 1899 as a nonprofit hospital, National Jewish remains the only facility in the world dedicated exclusively to these disorders. Since 1998, U.S. News & World Report has ranked National Jewish the #1 respiratory hospital in the nation.
